NOL7 and pancreatic adenocarcinoma: However, NOL7 expression showed no significant change during disease progression in several cancers, including cervical squamous cell carcinoma (CESC), PAAD, skin cutaneous melanoma (SKCM), and uterine corpus endometrial carcinoma (UCEC).